| Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update | 11/14 16:30 | globenewswire.com |
| Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference | 11/04 08:00 | globenewswire.com |
| Benitec Biopharma: OPMD Program Continues To Advance With Catalysts | 10/17 15:35 | seekingalpha.com |
| Benitec Biopharma Announces Updated Investor Webcast Information | 10/14 06:00 | globenewswire.com |
| Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society | 10/12 06:30 | globenewswire.com |
| Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update | 09/26 16:30 | globenewswire.com |
| Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society | 09/18 08:00 | globenewswire.com |
| Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study | 07/15 06:00 | globenewswire.com |
| Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update | 05/13 08:15 | globenewswire.com |
| Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study | 04/18 07:30 | globenewswire.com |